Login to Your Account



Clinic Roundup


Friday, August 23, 2013
• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it reached agreement with the FDA for two special protocol assessments for the company's pivotal Phase III program testing NAV5001 as an aid in the differential diagnosis of Parkinsonian syndromes from non-Parkinsonian tremor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription